427 related articles for article (PubMed ID: 20924261)
1. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T
Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
3. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
4. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic approaches to age-related macular degeneration today.
Bressler NM
Ophthalmology; 2009 Oct; 116(10 Suppl):S15-23. PubMed ID: 19800535
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
7. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
Barbazetto I; Saroj N; Shapiro H; Wong P; Freund KB
Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
[TBL] [Abstract][Full Text] [Related]
8. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
[TBL] [Abstract][Full Text] [Related]
10. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
11. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Boyer DS; Antoszyk AN; Awh CC; Bhisitkul RB; Shapiro H; Acharya NR;
Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials.
Rosenfeld PJ; Shapiro H; Tuomi L; Webster M; Elledge J; Blodi B;
Ophthalmology; 2011 Mar; 118(3):523-30. PubMed ID: 20920825
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.
Carneiro AM; Silva RM; Veludo MJ; Barbosa A; Ruiz-Moreno JM; Falcão MS; Brandão EM; Falcão-Reis FM
Ophthalmologica; 2011; 225(2):81-8. PubMed ID: 20881442
[TBL] [Abstract][Full Text] [Related]
14. Comparing ranibizumab with bevacizumab.
Biswas P; Sengupta S; Choudhary R; Home S; Paul A; Sinha S
Ophthalmology; 2011 Mar; 118(3):600-600.e2. PubMed ID: 21376243
[No Abstract] [Full Text] [Related]
15. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
16. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
17. Combined ranibizumab and photodynamic therapy to treat exudative age-related macular degeneration: an option for improving treatment efficiency.
Mataix J; Palacios E; Carmen DM; Garcia-Pous M; Navea A
Retina; 2010 Sep; 30(8):1190-6. PubMed ID: 20539256
[TBL] [Abstract][Full Text] [Related]
18. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials.
Barbazetto IA; Saroj N; Shapiro H; Wong P; Ho AC; Freund KB
Am J Ophthalmol; 2010 Jun; 149(6):939-946.e1. PubMed ID: 20378094
[TBL] [Abstract][Full Text] [Related]
19. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
20. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]